Ken Griffin T Scan Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 218,987 shares of TCRX stock, worth $422,644. This represents 0.0% of its overall portfolio holdings.
Number of Shares
218,987
Previous 54,392
302.61%
Holding current value
$422,644
Previous $75,000
322.67%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TCRX
# of Institutions
80Shares Held
37.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$15.2 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$10.1 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$8.61 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$5.37 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$4.15 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $36.5M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...